Moderna gave investors two things to weigh on Friday: a quarterly report that cleared expectations and a flu vaccine approval that opens a new commercial front. The stock’s 5.7% advance suggests the market read both as good news. The more demanding question is whether the company can grow faster while spending less on the research that fuels that growth.
A Wider Revenue Outlook, a Thinner Research Purse
Management now expects full-year 2026 revenue growth of 15% to 25%, a sharp upgrade from the prior guidance of up to 10%. At the same time, it trimmed projected research and development spending for 2026 to roughly $2.7 billion, down from $2.9 billion previously guided.
That pairing carries more weight than the headline beat. Lower outlays can magnify the earnings power of rising sales, but they also raise the bar: Moderna must deliver its planned pipeline milestones inside a smaller budget. The growth story only holds together if execution on both fronts does.
The Quarter Behind the Raise
Third-quarter 2026 revenue climbed 29% to $1.31 billion, according to Reuters, with diluted earnings per share of $0.38 and net income of $162 million. Moderna credited stronger international demand for its COVID-19 shots and deliveries under partnership arrangements.
The existing franchise, then, is doing the heavy lifting. That matters for how investors price everything else in the pipeline β the base business is producing results while newer programs sit at very different stages of maturity.
Two Pipeline Stories, Two Very Different Stages
The mFLUSIVA influenza vaccine has secured regulatory approval, giving the company’s vaccine portfolio a concrete, marketable addition. The melanoma program sits earlier on the curve: combined with KEYTRUDA, it reduced the risk of melanoma recurrence or death by 42% compared with KEYTRUDA alone.
That 42% figure is the heart of the oncology readout β a clinical advantage over the standard single-agent approach. It supports the case for the combination program, though the path to commercial use still depends on further progress. A regulatory green light and a mid-stage clinical result are not the same asset, and the market should not treat them as such.
Should investors sell immediately? Or is it worth buying Moderna?
A Legal Cloud Lifts, Without a Check Written
Moderna also closed a chapter on the patent front. As Reuters reported on October 28, the company settled its U.S. and European patent disputes with GSK over its COVID-19 and RSV vaccines. The agreement provides for mutual patent licenses covering infectious diseases and requires no payments.
No cash changes hands, but the resolution removes an overhang and adds a licensing framework to the operational news. It is a legal step forward that complements, rather than replaces, the commercial and clinical developments.
Mexico and the Durability Test
A manufacturing agreement with a local producer in Mexico offers another angle on staying power, supporting recurring revenue and international expansion. Its value hinges on whether it reliably generates repeat business β the same durability question that hangs over the whole investment case.
The next scheduled checkpoint is the analyst day on November 12, 2026, where management will be expected to show how the existing business and the newer applications fit together.
What Has to Go Right
The bull case rests on three pillars: faster growth, a leaner research budget, and a longer-term contract that broadens the revenue base. Revenue and profit describe the present, the flu approval marks a regulatory win, and the melanoma data offer a clinical promise. The breadth is genuinely encouraging. Whether it becomes a sustainably more profitable company depends on demand holding up and the pipeline advancing β inside the tighter budget Moderna has now set for itself.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from November 9 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 9.
Moderna: Buy or sell? Read more here...
